Peptide Comparison
CagriSema vs Mazdutide
Editorial breakdown of mechanism, evidence, decision criteria, and the misconceptions worth calling out.
Data-derived verdict
CagriSema and Mazdutide share the glp-1 class and carry roughly equivalent evidence (Phase 3 / Phase 3 (China)). On the catalogued data layer CagriSema has a slight edge: more cited sources or efficacy data on file. For most research framings either pick is defensible; CagriSema's evidence base is currently denser.
Evidence at a glance
FDA-approved Phase 3 Phase 2 / approved abroad Anecdotal + animal Preclinical / flagged
Shared safety considerations
Both compounds share these reported concerns: gi effects. Open each peptide page for the full risk paragraph and source citations.
Side-by-side
| CagriSema | Mazdutide | |
|---|---|---|
| Class | Amylin + GLP-1 combination | GLP-1/glucagon dual agonist |
| Drug class | Metabolic & Weight | Metabolic & Weight |
| Mechanism | Dual amylin + GLP-1 receptor agonism | Oxyntomodulin analog; activates GLP-1 and glucagon receptors |
| Route | SC injection | SC injection |
| Half-life | ~7 days | Long-acting weekly |
| Dosage (research) | 2.4 mg / 2.4 mg SC weekly | 3-9 mg SC weekly |
| Evidence tier | Phase 3 | Phase 3 (China) |
| Research depth | 113 indexed | 126 indexed |
| Availability | Investigational | Investigational |
| Reported risks | GI effects; Phase 3 REDEFINE mixed results | GI effects; no Western approval |
Reported research data only. "Studied for" and "reported in literature" describe published research focus, not clinical recommendation. Most peptides catalogued here are not FDA-approved for human use.
Frequently asked questions
Should I pick CagriSema or Mazdutide?
CagriSema and Mazdutide share the glp-1 class and carry roughly equivalent evidence (Phase 3 / Phase 3 (China)). On the catalogued data layer CagriSema has a slight edge: more cited sources or efficacy data on file. For most research framings either pick is defensible; CagriSema's evidence base is currently denser.
What is the difference between CagriSema and Mazdutide?
CagriSema is classed as Amylin + GLP-1 combination; Mazdutide is classed as GLP-1/glucagon dual agonist. Reported mechanism: CagriSema, Dual amylin + GLP-1 receptor agonism; Mazdutide, Oxyntomodulin analog; activates GLP-1 and glucagon receptors. Reported half-life: CagriSema, ~7 days; Mazdutide, Long-acting weekly. Routes in published studies: CagriSema, SC injection; Mazdutide, SC injection.
Which has stronger evidence, CagriSema or Mazdutide?
CagriSema and Mazdutide sit on the same rung of PeptideHelper.org's five-step evidence scale, which runs from preclinical to FDA-approved. CagriSema is graded Phase 3, with 25 cited sources on its reference page and 113 indexed studies. Mazdutide is graded Phase 3 (China), with 23 cited sources on its reference page and 126 indexed studies.
Which is more accessible, CagriSema or Mazdutide?
Neither CagriSema nor Mazdutide is an FDA-approved drug. Catalog status: CagriSema, Investigational; Mazdutide, Investigational.
Are CagriSema and Mazdutide ever combined?
CagriSema and Mazdutide appear together in no stack catalogued on PeptideHelper.org, and the interaction engine raises no flag for the pair.
Open the PeptideHelper.org compare tool to add more compounds to this side-by-side and filter by evidence tier interactively.
Loading interactive view…